Skip to main content
. 2024 Oct 9;12(10):1154. doi: 10.3390/vaccines12101154

Table 4.

Prevalence and concordance between clinician-collected anorectal swabs and serology to detect high risk, 4V, and 9V HPV among men who did not report receiving any doses of the HPV vaccine (n = 53).

HPV Type DNA Anorectal Swabs
n, %
Serology
n, %
% Agreement a Kappa (95% CI) McNemar’s p-Value
HR HPV b 17 32.1% 18 34.0% 56.6% 0.02 (−0.25 to 0.29) 1
4V HPV c 19 35.8% 25 47.2% 58.5% 0.16 (−0.10 to 0.42) 0.29
9V HPV d 25 47.2% 27 50.9% 54.7% 0.1 (−0.17 to 0.36) 0.84

a Percent agreement: Sum of results positive for both swabs/serology and negative for both swabs/serology out of all test results in unvaccinated MSM. b Detection of any high-risk HPV types: 16, 18, 31, 33, 35, 45, 52, 58. c Detection of any 4V HPV types: 6, 11, 16, 18. d Detection of any 9V HPV types: 6, 11, 16, 18, 31, 33, 45, 52, 58.

HHS Vulnerability Disclosure